Renal safety after one year of sofosbuvir‐based therapy for chronic hepatitis C: A Brazilian “real‐life” study.

Summary: What is known and objective: Sofosbuvir(SOF)‐based regimens have been administrated with excellent efficacy in chronic hepatitis C. Few uncontrolled (“real‐life”) studies consider the assessment of renal function when evaluating their post‐treatment outcomes. This study aims to evaluate renal biomarkers in a “real‐life” experience with chronic hepatitis C patients treated with SOF therapy in a long‐term follow‐up. Methods: Serum and urinary biomarkers were analysed before, at the end of therapy (EoT), after 12 weeks (sustained virological response—SVR) and one year (1y) post‐treatment. Patients were categorized according to baseline glomerular filtration rate (GFR—cut‐off 45 mL/min/1.73 m2). Results: Ninety‐four patients with a mean age of 59.9 ± 8.5 years were included; 98.9% of patients reached SVR. Significant improvement in renal biomarkers was observed in patients with GFR ≥45 mL/min/1.73 m2, as indicated by a progressive increase in mean GFR values until 1y. No evidence of tubular dysfunction was identified. Patients with baseline GFR <45 mL/min/1.73 m2 did not experience alterations in renal biomarkers; however, a mean change of +10.7 in GFR values was observed. We noticed significant upper stage transition in the CKD classification, and 58.7% of patients achieved G1 stage at 1y (P < .0001). What is new and conclusion: In a “real‐life experience” of a Brazilian centre, SOF therapy appears to guarantee renal safety for patients with chronic hepatitis C followed until one year after treatment. [ABSTRACT FROM AUTHOR]